Exodus Point Capital Management, LP C4 Therapeutics, Inc. Transaction History
Exodus Point Capital Management, LP
- $14.6 Billion
- Q4 2024
A detailed history of Exodus Point Capital Management, LP transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 59,654 shares of CCCC stock, worth $126,466. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,654Holding current value
$126,466% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding CCCC
# of Institutions
125Shares Held
62.7MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$14.8 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$14.5 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$12.9 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$10.3 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$9.65 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $104M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...